| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IRON | Common Stock | Options Exercise | $65.5K | +1.72K | $38.00 | 1.72K | Dec 18, 2023 | Direct | F1 | |
| transaction | IRON | Common Stock | Sale | -$102K | -1.72K | -100% | $59.24 | 0 | Dec 18, 2023 | Direct | |
| holding | IRON | Common Stock | 580K | Dec 18, 2023 | See footnotes | F2, F5 | |||||
| holding | IRON | Common Stock | 898K | Dec 18, 2023 | See footnotes | F3, F5 | |||||
| holding | IRON | Common Stock | 224K | Dec 18, 2023 | See footnotes | F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IRON | Stock Options (Right to Buy) | Options Exercise | $0 | -1.72K | -100% | $0.00* | 0 | Dec 18, 2023 | Common Stock | 1.72K | $38.00 | Direct | F1, F6 |
| Id | Content |
|---|---|
| F1 | Represents the exercise of stock options granted to Carl L. Gordon ("Gordon") on October 4, 2021 by Gemini Therapeutics, Inc. ("Gemini"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. ("Disc"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC ("OrbiMed Advisors") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors. |
| F2 | These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI. |
| F3 | These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. |
| F4 | These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. |
| F5 | This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. |
| F6 | These stock options vested on October 4, 2022. |